Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis

Vascular

Volumn 9, Issue 3, 2001, Pages 211-218

  Money, Samuel R ^a   York, John W ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

anticoagulants; delivery agent; DVT; oral heparin; SNAC; SNAD

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OCTANOIC ACID DERIVATIVE; SODIUM N (8[2 HYDROXYBENZOYL]AMINO) CAPRYLATE; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; INTERNAL JUGULAR VEIN; INTESTINE ABSORPTION; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; SHORT SURVEY; SIDE EFFECT; THROMBOGENESIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBIN III; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DECANOATES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; HEPARIN; HUMANS; HYDROXYBENZOIC ACIDS; INTESTINAL ABSORPTION; OCTANOIC ACIDS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0035038087     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721090100900302     Document Type: Review

References (15)

1. Hirsh, J. Heparin. New England Journal of Medicine, 1991, 324, 1565-1574.
2. Anderson, F. A. Wheeler, H. B. Goldberg, R. J. et al. A population-based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: the Worchester DVT Study. Archives of internal Medicine, 1991, 151, 933-938.
3. Peterson, K. L. Acute pulmonary thromboembolism: Has its evolution been redefined. Circulation, 1999, 99, 1280-1283.
4. Hull, R. D. Pineo, G. F. Raskob, G. E. The economic impact of treating deep vein thrombosis with low molecular weight heparin: outcome of therapy and health economy aspects. Haemostasis, 1998, 28(Suppl 3), 8-16.
5. Mueller, R. L. Scheidt, S. History of drugs for thrombotic disease, discovery, development, and directions for the future. Circulation, 1994, 89, 432-449.
6. Hirsh, J. Dalen, J. E. Poller, L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest, 1992, 4, 337s-351s.
7. Wessler, S. Sanford, N. G. Pharmacology of heparin and warfarin. Journal of the American College of Cardiology, 1986, 8, 10B-20B.
8. Rivera, T. M. Leone-Bay, A. Paton, D. R. et al. Oral delivery of heparin in combination with SNAC: pharmacologic considerations. Pharmacologic Research, 1997, 14, 1830-1833.
9. Gonze, M. D. Salartash, K. Sternbergh, W. C. III, et al. Orally administered unfractionated heparin with carrier agent is therapeutic for deep vein thrombosis. Circulation, 2000, 101, 2658-2661.
10. Salatash, K. Gonze, M. D. Leone-Bay, A. et al. Oral low molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. Journal of Vascular Surgery, 1999, 30, 526-532.
11. Gonze, M. D. Manord, J. D. Leone-Bay, A. et al. Orally administered heparin for preventing deep venous thrombosis. American Journal of Surgery, 1998, 176, 176-178.
12. Blake, A. Ashwin, T. Jacques, L. B. An assay for the antithrombotic activity of anticoagulants. Journal of Clinical Pathology, 1959, 12, 118-122.
13. Hosaka, J. Roy, S. Kvernebo, K. et al. Induced thrombus in the pig vena cava: a model of deep venous thrombosis. Journal of Vascular and Interventional Radiology, 1996, 7, 395-400.
14. Salartash, K. Lepore, M. Gonze, M. D. et al. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Annals of Surgery, 2000, 231(6), 989-994.
15. Baughman, R. A. Kapore, S. C. Agawal, R. K. et al. Oral delivery of anticoagulant doses of heparin, a randomized, double blind, controlled study in humans. Circulation, 1998, 98, 1610-1615.